Psoriasis is a skin condition that causes individuals to develop a rash with scaly, itchy patches on their elbows, knees, trunk and scalp. This chronic illness, which may start off as a few itchy patches, can severely affect an individual’s quality of life.
Psoriasis is often accompanied by chronic inflammation, which affects those with mild and severe cases alike. Experts agree that in the absence of a cure, proper treatment is required to manage the condition.
Below we look at what happens when psoriasis remains untreated and any complications that may arise from undertreating or not treating the condition.
What to expect in the short- and long-term for untreated psoriasis?
Given that the condition causes itching in the beginning, it makes sense that leaving psoriasis untreated in the short-term will result in even more itching and discomfort. Spectrum Skin and Laser founder and dermatologic surgeon, Dr. Jeremy Brauer, states that intense itching will result in opened lesions that can become infected.
Psoriasis may also affect other organ systems, including the heart and cardiovascular system, as well as the skeletal system and the joints. This means that improper or no treatment heighten an individual’s health risks.
In addition to this, Brauer highlights that psoriasis that isn’t treated may also affect persons psychologically because it takes a physical and emotional toll and impairs a person’s quality of life, which in turn affects relationships and ability to perform daily tasks.
Patients who do not undergo treatment may also notice the presence of new patches on their body.
If psoriasis remains untreated in the long-term, other complications may begin to set in. Those complications include joint pain, chronic inflammation and limited mobility around the area affected.
Additionally, some comorbidities may be caused or worsened by untreated psoriasis. They include:
Psoriatic arthritis
Inflammation worsening in patients with psoriasis may develop into psoriatic arthritis. Recent studies have found that the possibility of the condition becoming arthritic is 20% after three decades. Mount Sinai Hospital dermatologist, Dr. Carmen Castilla, adds that patients with psoriatic arthritis may also suffer from permanent joint damage if they don’t undergo treatment.
Nonalcoholic fatty liver disease
Findings published in “Advances in Dermatology and Allergology” highlight that an individual’s risk of fatty liver disease increases if they have psoriasis.
Kidney disease
Research has also determined that psoriasis patients had a considerably higher risk of developing chronic kidney disease and end-state renal disease. This link may boil down to the fact that psoriatic patients have a heightened risk of developing hypertension and diabetes, which are both risk factors for kidney disease.
Psychological disorders
One 2022 study, whose findings were reported in “Psoriasis: Targets and Therapy,” found that the mental health fallout from untreated psoriasis included depression, anxiety, substance misuse and suicidal ideation.
As the discussion above shows, psoriasis can have far-reaching effects if it remains untreated or isn’t treated appropriately. These potential complications could be the reason why enterprises such as Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are working to develop treatments with higher efficacy against psoriasis so that patients don’t get exposed to complications arising from undertreatment of the primary skin condition.
NOTE TO INVESTORS: The latest news and updates relating to Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
The FDA IND approval marks a pivotal step for the company's lead compound, known as…
Cancer care has evolved over the past decades and one would expect that the more…
In the United States alone, close to one million people are living with MS, with…
A nationwide survey conducted by the Commonwealth Fund has found that contrary to a common…
Earth Science Tech has uplisted to the OTCQB Venture Market, a premier public market that…
VERAXA is advancing an oncology pipeline centered on its proprietary BiTAC(R) platform, alongside additional antibody-drug…